Zurcher Kantonalbank Zurich Cantonalbank Boosts Position in IQVIA Holdings Inc. (NYSE:IQV)

Zurcher Kantonalbank Zurich Cantonalbank grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 34.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,603 shares of the medical research company’s stock after buying an additional 25,778 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in IQVIA were worth $23,840,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. PGGM Investments increased its holdings in IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after acquiring an additional 4,326 shares in the last quarter. Simplify Asset Management Inc. increased its stake in shares of IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Raymond James & Associates raised its position in shares of IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock worth $169,231,000 after purchasing an additional 5,417 shares during the last quarter. Versor Investments LP purchased a new stake in IQVIA in the 3rd quarter valued at approximately $1,328,000. Finally, Gradient Investments LLC increased its position in IQVIA by 15.6% during the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after buying an additional 6,134 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $200.96 on Friday. The firm has a market capitalization of $36.47 billion, a PE ratio of 26.37, a P/E/G ratio of 2.07 and a beta of 1.51. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The business has a 50-day moving average of $218.67 and a two-hundred day moving average of $226.20.

Analyst Ratings Changes

IQV has been the topic of several recent research reports. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Friday, November 1st. Robert W. Baird decreased their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. cut their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Evercore ISI decreased their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, BTIG Research cut their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.